Skip to main content

04-06-2021 | EULAR 2021 | Conference coverage | Video

COSMOS: Further evidence for the benefits of guselkumab in PsA

Laura Coates outlines the findings from a phase 3b trial of guselkumab versus placebo in patients with psoriatic arthritis and an inadequate response to TNF inhibitors (6:03).

Read transcript

EULAR 2021 Virtual Congress coverage

Access news and expert commentary from the EULAR 2021 Virtual Congress.

Image Credits